Clinical trials: Complication of Peritoneal Dialysis
End Stage Renal Disease
A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)
This study is designed to assess the pharmacokinetics (PK) and safety of oseltamivir and its metabolite oseltamivir carboxylate in participants undergoing routine HD and CAPD for end-stage renal disease (ESRD).
- Trial name
- NCT02617784
- Testing
- Oseltamivir
- Where
- New Zealand
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease, Hyperparathyroidism
Pediatric Chronic Kidney Disease Safety and Efficacy
The purpose of this study is to assess the safety and efficacy of adding cinacalcet to the current treatment of secondary hyperparathyroidism in children currently receiving dialysis compared to a treatment regimen that does not…
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease
- Trial name
- NCT01277510
- Testing
- cinacalcet capsule, Standard of Care
- Where
- 51 sites in United States, Australia and 8 more
- Volunteers
- 43 people
- Sponsor
- Amgen
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in PD US Trial
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02468414
- Testing
- MDGN201 TARGTEPO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Dialysis, Anemia
Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment
The purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with end-stage renal disease who recently started dialysis.
- Trial name
- NCT01414075
- Testing
- Roxadustat, Oral Iron, IV Iron
- Where
- 7 sites in United States, Hong Kong and 2 more
- Volunteers
- 60 people
- Sponsor
- Kyntra Bio
Anemia, Kidney Failure
Dynepo Infrequent Dosing Study
The purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly and once weekly dose schedule of Dynepo in previously erythropoietin (EPO)-naive patients, as measured by haemoglobin at week 24 and…
- Trial name
- NCT00450333
- Testing
- Dynepo (Epoetin delta), Dynepo
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 407 people
- Sponsor
- Shire
Chronic Kidney Disease, Bacterial Infection
Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease
The purpose of this study is to: 1. Study the pharmacokinetics and safety of daptomycin in children on hemodialysis (HD) and peritoneal dialysis (PD). 2. Determine urine, HD and PD clearance of daptomycin.
- Trial name
- NCT01012089
- Testing
- Daptomycin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Oklahoma
End-Stage Renal Disease
L-Carnitine in Peritoneal Dialysis
The development of glucose-sparing strategies able to provide an efficacious ultrafiltration profile represents one of the modern goals of peritoneal dialysis therapy.
- Trial name
- NCT00922701
- Testing
- L-carnitine
- Where
- Italy
- Volunteers
- 4 people
- Sponsor
- Iperboreal Pharma Srl
Kidney Failure, Chronic, Peritoneal Dialysis Complication
Improving Care for Peritoneal Dialysis Patients With the CKD-PD App
Managing the hydration status in patients undergoing peritoneal dialysis (PD) is a key task for nephrologists in Thailand that is made difficult due to lack of timely access to hydration metrics including weight, blood pressure…
- Trial name
- NCT04797195
- Testing
- CKD-PD app with home monitoring equipment
- Where
- 3 sites in Thailand
- Volunteers
- 208 people
- Sponsor
- Massachusetts General Hospital
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02378662
- Testing
- MDGN201 TARGTEPO
- Where
- 2 sites in Israel
- Volunteers
- 2 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Hyperphosphatemia, Kidney Failure
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to placebo for 4 weeks.
- Trial name
- NCT01191255
- Where
- 56 sites in United States, Israel and 1 more
- Volunteers
- 441 people
- Sponsor
- Keryx Biopharmaceuticals